Thus, at this moment, anti-VEGF/VEGFR (vascular endothelial growth factor/vascular endothelial growth factor receptor) monoclonal antibodies, antisense suppression of VEGF, VEGFR tyrosine kinase inhibitors, viral-directed targeting of VEGFR signaling or the use of endogenous angiogenic inhibitors are under investigation as potential adjuvants to radiation in the cancer treatment [92]. This evidence concerns the gene KDR and cancer.